Virender Bhan

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Incidence of acquired demyelination of the CNS in Canadian children

Brenda Banwell, J. Kennedy, Douglas L. Arnold et al. · Neurology · 2009 · 368 citations

Medicine, Neurology, Pediatrics +17

Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study

Brenda Banwell, Lauren Krupp, Julia Kennedy et al. · The Lancet Neurology · 2007 · 346 citations

Medicine, Neurology, Pediatrics +15

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study

Brenda Banwell, Amit Bar‐Or, Douglas L. Arnold et al. · The Lancet Neurology · 2011 · 318 citations

Medicine, Neurology, Pediatrics +17